Numerous studies have demonstrated that HPV vaccination is cost-effective, particularly when administered to preteens before they become sexually active. The reduction in healthcare costs associated with treating HPV-related diseases, including cancers and genital warts, outweighs the costs of vaccination programs. Furthermore, significant public health benefits are associated with reduced morbidity and mortality from these conditions.
